Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556467 | 0.90 | RORC (0.40) | RORCJAK2JAK1ALKUSP30 | |
| SCHEMBL534534 | 0.84 | OPRD1 (0.36) | RORC | |
| SCHEMBL556678 | 0.84 | RORC (0.40) | RORCJAK2JAK1ALKUSP30 | |
| SCHEMBL556101 | 0.82 | RORC (0.41) | RORCJAK2JAK1ALKUSP30 | |
| SCHEMBL556118 | 0.82 | OPRD1 (0.41) | RORCJAK2JAK1DPP4ADAMTS5 | |
| SCHEMBL555700 | 0.80 | RORC (0.39) | RORCJAK2JAK1ALKUSP30 | |
| SCHEMBL557331 | 0.80 | RORC (0.39) | RORCJAK2JAK1ALKUSP30 | |
| SCHEMBL2352484 | 0.77 | RORC (0.46) | RORCJAK2JAK1DPP4GPR119 | |
| SCHEMBL29532756 | 0.77 | RORC (0.46) | RORCJAK2JAK1DPP4GPR119 | |
| SCHEMBL16434896 | 0.76 | ALK (0.47) | RORCALKUSP30GPR119TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | RORC 2021/4885JAK2 3495/4885JAK1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.